Literature DB >> 12470135

Soluble Fas ligand and transforming growth factor beta2 in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty.

Thomas Reinhard1, Halvard Bönig, Susanne Mayweg, Daniel Böhringer, Ulrich Göbel, Rainer Sundmacher.   

Abstract

BACKGROUND: Excellent long-term prognosis of penetrating corneal grafts has been explained by the immunological privilege of the cornea and the anterior chamber. In animal models the secretion of transforming growth factor beta(2) (TGF-beta(2)) into the anterior chamber and the expression of the Fas ligand on corneal endothelial cells were identified as important for the integrity of the immunological privilege.
OBJECTIVE: To determine the TGF-beta(2) and soluble Fas ligand (sFasL) levels in the aqueous humor of patients after penetrating keratoplasty (PK) who have and who do not have immune reactions.
METHODS: Anterior chamber puncture was performed in 13 patients who had a cataract without PK (group 1), in 31 patients after PK who did not have immune reactions (group 2), and in 12 patients after PK newly diagnosed as having endothelial immune reactions (group 3). Total TGF-beta(2) and sFasL were determined via enzyme-linked immunosorbent assay.
RESULTS: Transforming growth factor beta(2) was detected in all patients, irrespective of the underlying condition; there was no difference in TGF-beta(2) levels between the different groups (P =.89, analysis of variance). None of the patients in group 1, 11 of 31 patients in group 2, and 8 of 12 patients in group 3 had detectable sFasL concentrations (P =.002, chi(2) test). Soluble Fas ligand averaged (mean [SD]) 20.8 (31.1) pg/mL in group 2, and 38.1 (33.2) pg/mL (P<.01, analysis of variance) in group 3.
CONCLUSIONS: It appears that total TGF-beta(2) is maintained at high steady-state levels, while the level of sFasL is up-regulated in patients who underwent PK, particularily in the advent of graft rejection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470135     DOI: 10.1001/archopht.120.12.1630

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  [Intracameral application of corticosteroids for treating severe endothelial rejection after penetrating keratoplasty].

Authors:  F Birnbaum; P Maier; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

Review 2.  [Topical immunosuppressives after penetrating keratoplasty].

Authors:  F Birnbaum; A Reis; T Reinhard
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

3.  Total protein concentration and T-cell suppression activity of aqueous humour before and after penetrating keratoplasty.

Authors:  J-S Mo; P Maier; D Böhringer; H Reinshagen; R Sundmacher; T Reinhard
Journal:  Eye (Lond)       Date:  2011-11-18       Impact factor: 3.775

Review 4.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

5.  Predicting the risk for corneal graft rejection by aqueous humor analysis.

Authors:  Philip Maier; Ulrike Heizmann; Daniel Böhringer; Yvonne Kern; Thomas Reinhard
Journal:  Mol Vis       Date:  2011-04-25       Impact factor: 2.367

6.  Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment.

Authors:  Ting Zhang; Zhiyuan Li; Ting Liu; Suxia Li; Hua Gao; Chao Wei; Weiyun Shi
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

7.  Distinct cytokine pattern in aqueous humor during immune reactions following penetrating keratoplasty.

Authors:  Philip Maier; Ulrike Heizmann; Daniel Böhringer; Yvonne Kern; Thomas Reinhard
Journal:  Mol Vis       Date:  2010-01-15       Impact factor: 2.367

8.  Activation of human macrophages by human corneal allogen in vitro.

Authors:  Paola Kammrath Betancor; Antonia Hildebrand; Daniel Böhringer; Florian Emmerich; Günther Schlunck; Thomas Reinhard; Thabo Lapp
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.